Investor Relations
Corporate Profile
We are a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS), with the goal of improving patients’ lives.
Minimum 15 minutes delayed. Source: LSEG
Latest Presentations
March 26, 2026
Press Releases
Events & Presentations
December 18, 2025 at 8:30 AM EST